Phase I Durvalumab and Tremelimumab With Radiotherapy for Adjuvant Treatment of Intermediate Risk SCCHN

Conditions:   Larynx;   Lip;   Oral Cancer;   Digestive Organs--Diseases
Interventions:   Drug: Durvalumab;   Radiation: Intensity Modulated Radiotherapy Treatments;   Drug: Tremelimumab
Sponsors:   UNC Lineberger Comprehensive Cancer Center;   AstraZeneca
Not yet recruiting

https://ift.tt/2L6RvQB